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Abstract. Primary progressive aphasia (PPA) represents a diverse group of language-led dementias most often due to frontotem-
poral lobar degeneration. We report clinical, neuropsychological, and neuroimaging data in the case of a 47-year-old woman
presenting with non-fluent PPA due to a genetically confirmed pathogenic presenilin 1 P264L mutation. This case highlights an
unusual clinical presentation of familial Alzheimer’s disease and a novel presentation of the P264L mutation. The case adds to
accumulating evidence that particular mutations can promote specific brain network degeneration, with wider implications for
understanding the sporadic forms of Alzheimer’s disease and PPA.
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INTRODUCTION
The primary progressive aphasias (PPA) are
language-led dementias comprising three major clin-
ical syndromes [1]: a non-fluent/agrammatic variant
(nv-PPA) associated with apraxia of speech, agram-
matism, and left peri-sylvian atrophy; a semantic
variant (sv-PPA) associated with loss of semantic
knowledge and anterior temporal lobe atrophy; and
a logopenic variant (lv-PPA) associated with single-
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word retrieval deficits, impaired phonological working
memory, and left temporo-parietal atrophy. nv-PPA
and sv-PPA are typically associated with pathology in
the frontotemporal lobar degeneration (FTLD) spec-
trum [2], while lv-PPA is most often associated with
Alzheimer’s disease (AD) pathology [2]. Autosomal
dominant forms of PPA are uncommon but are most
often attributable to mutations in the progranulin,
microtubule associated protein tau or C9ORF72 genes
[3–5]. Autosomal dominant AD is also uncommon,
typically presenting as a progressive amnestic syn-
drome [6] and results from mutations in the presenilin
1 (PSEN1), presenilin 2 (PSEN2), or amyloid pre-
cursor protein (APP) genes. In particular, the P264L
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Table 1
Summary of patient’s neuropsychological performance. Raw scores
and percentile rankings are shown. Results <5th percentile of pub-
lished norms are shown in bold
Raw Score Percentile¶
IQ
WASI Vebal IQ 77
WASI Performance IQ 68
Episodic memory
Recognition Memory Test-Words (/50) 45 50th
Recognition Memory Test-Faces (/50) 43 25–50th
Executive function
D-KEFS Stroop word 60 <1st
D-KEFS Stroop inhibition 150 <1st
Semantic processing
British Picture Vocabulary Test (/150) 136 25–50th
Language skills
Graded non-word repetition /20 12 <1st
Graded non-word reading /25 13 1–5th
Sentence repetition /10 6 <1st
Verb Naming /20 19 <1st
Graded Word Repetition /45 39 1–5th
PALPA 55 sentence comprehension /24 20 <25th
Graded Naming Test (/30) 0 <1st
Boston Naming Test (/30) 6 <1st
Other Skills
Digit Span-Forward (/12) 4 <5th
Digit Span-Reverse (/12) 3 5–25th
Addition 0 <1st
Subtraction 1 1st–5th
Visual Object Spatial Perception 13 1st–5th
D-KEFS Stroop (word and inhibition), Delis-Kaplan executive func-
tion system; PALPA 55, Psycholinguistic Assessment of Language
Processing in Aphasia; WASI, Wechsler Abbreviated Scale of Intelli-
gence. ¶Where published normative percentile data are unavailable,
percentile values relative to local control data (n= 75) are listed.
PSEN1 mutation usually presents with typical amnes-
tic AD, and rarely with less typical phenotypes such as
dementia with Lewy bodies or frontotemporal demen-
tia (see Supplementary Table 1; available online:
http://dx.doi.org/10.3233/JAD-122092) [7–15]. Here,
we report clinical, neuropsychological, and neu-
roimaging data signifying a novel presentation of
this mutation in a patient with PPA. Ethical approval
for the study was obtained from the London Queen
Square Ethics Committee and the subject gave written
informed consent to participate in accordance with the
Declaration of Helsinki.
CASE REPORT
The patient, a right handed charity administrator,
presented initially at age 45 with an approximately
three year history of increasingly effortful speech and
word-finding difficulty. The patient had no relevant
past medical history. At that stage, there was no objec-
tive language or other cognitive deficits demonstrable
on bedside assessment. Over the following two years,
she suffered an insidious deterioration in her expres-
sive speech and handwriting with prominent errors of
grammar and spelling, and she developed significant
anxiety around these symptoms. However, no concerns
were raised by family members regarding her episodic
memory or behavior. When reassessed at age 47, her
speech was effortful and marred by speech sound and
grammatical errors. There was a potentially relevant
family history: one of her parents had developed cogni-
tive decline with onset around 60 marked by insidious
behavioral change and episodic memory difficulties
and a clinical duration of 14 years.
The patient’s neuropsychological assessment con-
firmed a predominantly language-led cognitive syn-
drome consistent with current consensus criteria and
diagnostic formulations for nv-PPA (Table 1) [1].
She showed evidence of impaired repetition of single
polysyllabic words and sentences particularly affect-
ing non-words. Her comprehension of syntactically
complex sentences was also impaired. Despite severe
anomia, the patient’s semantic knowledge as mea-
sured by a test of single word comprehension (British
Picture Vocabulary score) was preserved. In addition
she exhibited executive dysfunction, while her perfor-
mance on verbal and visual recognition memory tests
was good. The general neurological examination was
unremarkable.
Volumetric MR brain imaging (Fig. 1A) revealed
global volume loss accentuated within the left cerebral
hemisphere. In particular, there was left-sided anterior
peri-Sylvian volume loss extending caudally to involve
parietal cortex. Metabolic brain imaging using FDG-
PET (Fig. 1B) identified asymmetric hypometabolism
within the left hemisphere, most strikingly within the
left temporal and parietal lobes. Diffusion weighted
imaging (B = 1000 s/mm2) was also carried out (see
Supplementary Figure 1). No areas of restricted dif-
fusion were identified, nor was there any cortical
ribboning consistent with prion disease present.
The clinical and neuroimaging evidence here sug-
gested a neurodegenerative disease with asymmetric
involvement of the cerebral hemispheres.
MATERIALS AND METHODS
Cerebrospinal fluid (CSF) was assayed to determine
levels of marker proteins associated with neurodegen-
eration and of value in discriminating FTLD from AD.
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Fig. 1. A) Representative coronal volumetric MRI and B) FDG-PET slices from patient with nv-PPA carrying the P264L presenilin mutation.
Arrow indicates left peri-sylvian volume loss and preserved hippocampi. B) FDG-PET scan indicating patterns of hypometabolism particularly
in left temporal and parietal cortices.
CSF total tau (a measure of neuronal loss, reflecting
non-specific neurodegeneration) and amyloid-1-42
(A42, a measure of amyloid deposition specific for
AD pathology) were assayed (Innotest platforms, Inno-
genetics, Ghent, Belgium). Total tau was elevated
(1400 pg/ml; >90% of all patients (n= 238) at our cen-
ter who have CSF and a clinical diagnosis of AD
have a total tau >1200 pg/ml), corroborating the clin-
ical impression of a neurodegenerative process. A42
was low (379 pg/ml; 85% of patients (n= 238) at our
center who have CSF and a clinical diagnosis of AD
have an A42 <400 pg/ml) and in keeping with previ-
ous reports of abnormal A42 levels [16]. The ratio of
tau:A42 was raised (3.7), consistent with AD pathol-
ogy (>90% all patients at our center who have CSF and
a clinical diagnosis of AD have a total tau/A42 >1).
14-3-3 protein was negative.
The first diagnostic consideration in this case in
light of the clinical and neuroimaging evidence was
a disease in the FTLD spectrum; the patient’s age
and family history further suggested a genetic basis
for her presentation, although there were no other liv-
ing affected relatives and no family members in the
previous generation had undergone genetic testing.
However, the CSF profile with a raised total tau:A42
ratio favored underlying AD pathology. We therefore
undertook direct Sanger sequencing of exons 16 and
17 of APP, exons 2–12 of PSEN1, and exon 4, 5, and
7 of PSEN2 using previously published methods [17].
We identified a heterozygous pathogenic point muta-
tion at exon 8 (g.49976C > T) in the PSEN1 gene (the
P264L mutation). Given the atypical presentation we
also screened for other mutations within the follow-
ing genes MAPT, GRN, C9ORF72, fused-in-sarcoma,
valosin-containing protein, prion protein, TAR DNA-
binding protein 43, and colony stimulating factor 1
receptor, with next generation sequencing technology
using Life Technology’s Ion Torrent PGM sequencing.
We found no further mutations or obvious variants of
unknown significance.
DISCUSSION
This case raises a number of important issues.
First, the clinical phenotype, consistent with nv-
PPA, represents a novel presentation of the PSEN1
P264L mutation. Schema for classifying familial AD
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mutations and functional cellular work have suggested
that this mutation is pathogenic. It is therefore highly
unlikely that another disease process accounted for the
atypical clinical phenotype in this case [18, 19]. While
language deficits, in particular anomia, are common in
familial AD, these tend to manifest later in the illness
with only one previous case due to a different mutation
(PSEN1 R278I) reported as presenting with nv-PPA
[20, 21]. Second, this case highlights the heterogeneity
of the P264L mutation. This is evident both in relation
to previously published cases (Supplementary Table 1)
[7–15, 20] and reported clinical phenotypes within the
patient’s family. While detailed clinical information
about the previous generation is lacking, the substan-
tially later age of the patient’s father at clinical onset
and his clinical phenotype (a memory/behavioral led
syndrome) suggests that if (as is plausible) he also car-
ried the P264L mutation, then the clinical phenotype
of the mutation varied within this family. Indeed, a
recent report has highlighted the potential heterogene-
ity of this mutation among members of a single family;
one member had word comprehension deficits, while
another had more typical features of AD with poor
episodic memory and apraxia [14].
The present case supports the idea that genetic
lesions may cause relatively focal cognitive presenta-
tions resulting from targeted degeneration of specific
vulnerable brain networks, here the left temporo-
parietal language network as demonstrated by clinical
and neuroimaging findings. This hypothesis is sup-
ported by studies of the language-led forms of sporadic
AD, most often presenting as lv-PPA, which also
show a similar distribution of neurodegeneration [1,
2, 22]. Indeed our patient’s phenotype overlapped
on clinical and neuroimaging grounds with lv-PPA,
although did not fulfill current criteria for lv-PPA
(owing to the presence of impaired motor speech
production and expressive agrammatism [1]). The
frequently observed overlap of neurodegenerative syn-
dromes might plausibly reflect disease propagation
through distributed functional networks [22, 23]. The
mechanisms by which brain networks are rendered
vulnerable and subsequently degenerate remain to
be elucidated. It may be that a pathogenic protein
change alters a vulnerable brain network via direct
toxicity or that protein alterations confer vulnerabil-
ity to existing protein species (e.g., A). Once the
degenerative process is triggered, the intrinsic net-
work connectivity may facilitate propagation of the
process, initially to locally connected brain regions
but ultimately, more diffusely. Rare genetic presen-
tations may help us understand how more common
sporadic disease develops and propagates within the
brain.
From a clinical perspective, the present case sug-
gests that screening for AD mutations should be
considered in patients presenting with PPA, particu-
larly where there is suspicion of a family history with
CSF or other pointers to underlying AD pathology or
when screens for other mutations causing FTLD are
negative.
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